Were Analysts Bullish TrovaGene, Inc. (NASDAQ:TROV) This Week?

July 11, 2018 - By Margaret Downey

TrovaGene, Inc. (NASDAQ:TROV) LogoInvestors sentiment increased to 0.75 in 2018 Q1. Its up 0.22, from 0.53 in 2017Q4. It improved, as 4 investors sold TrovaGene, Inc. shares while 8 reduced holdings. 7 funds opened positions while 2 raised stakes. 2.63 million shares or 7.88% more from 2.44 million shares in 2017Q4 were reported.
Wells Fargo Mn holds 500 shares or 0% of its portfolio. Polaris Greystone Gru Lc reported 12,000 shares or 0% of all its holdings. 100 are owned by Tci Wealth Advsr Inc. Royal Fincl Bank Of Canada stated it has 20 shares or 0% of all its holdings. State Bank Of Montreal Can, a Ontario – Canada-based fund reported 22,500 shares. Barclays Public Ltd Llc owns 25,000 shares for 0% of their portfolio. State Street reported 13,300 shares. Geode Capital Ltd Liability Corp has 139,330 shares. Renaissance Technology Ltd invested 0% in TrovaGene, Inc. (NASDAQ:TROV). Susquehanna Gp Limited Liability Partnership reported 44,763 shares. Northern Tru has invested 0% in TrovaGene, Inc. (NASDAQ:TROV). Retail Bank Of New York Mellon Corp owns 31,953 shares or 0% of their US portfolio. Bnp Paribas Arbitrage Sa holds 0% or 21 shares. 398,693 were accumulated by Blackrock. Cwm Ltd Limited Liability Company stated it has 0% of its portfolio in TrovaGene, Inc. (NASDAQ:TROV).

TrovaGene, Inc. (NASDAQ:TROV) Ratings Coverage

Among 2 analysts covering TrovaGene (NASDAQ:TROV), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. TrovaGene had 5 analyst reports since March 6, 2018 according to SRatingsIntel. On Monday, June 11 the stock rating was maintained by H.C. Wainwright with “Buy”. The firm has “Buy” rating by H.C. Wainwright given on Tuesday, March 6. As per Monday, June 4, the company rating was maintained by H.C. Wainwright. H.C. Wainwright maintained the shares of TROV in report on Tuesday, June 19 with “Buy” rating. The firm has “Buy” rating given on Friday, June 15 by Maxim Group. Below is a list of TrovaGene, Inc. (NASDAQ:TROV) latest ratings and price target changes.

19/06/2018 Broker: H.C. Wainwright Rating: Buy New Target: $2.5000 Maintain
15/06/2018 Broker: Maxim Group Old Rating: Hold New Rating: Buy Upgrade
11/06/2018 Broker: H.C. Wainwright Rating: Buy New Target: $2.5000 Maintain
04/06/2018 Broker: H.C. Wainwright Rating: Buy New Target: $7.0000 Maintain
06/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $1.0 Maintain

The stock increased 1.75% or $0.01 during the last trading session, reaching $0.75. About 810,918 shares traded or 36.08% up from the average. TrovaGene, Inc. (NASDAQ:TROV) has declined 63.33% since July 11, 2017 and is downtrending. It has underperformed by 75.90% the S&P500.

Trovagene, Inc., a molecular diagnostic company, focuses on the development and commercialization of proprietary molecular genetic detection technology for use in pharmaceutical development, clinical research, and medical testing in various clinical disciplines in the United States. The company has market cap of $17.21 million. The firm intends to enhance the treatment outcomes for cancer patients through its proprietary technology to detect and quantitatively monitor circulating tumor DNA using urine or blood samples. It currently has negative earnings. It offers Precision Cancer Monitoring (PCM) platform, which provides cancer monitoring by tracking and quantifying levels of ctDNA from either urine or blood samples, as well as intends to offer clinical information beyond the current standard of care.

Another recent and important TrovaGene, Inc. (NASDAQ:TROV) news was published by Streetinsider.com which published an article titled: “Trovagene (TROV) Announces Outlook for Second Half of 2018” on July 09, 2018.

TrovaGene, Inc. (NASDAQ:TROV) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: